BiotechTube
BioTheraVision

BioTheraVision

Irvine, United States· Est.
biotheravision.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

BioTheraVision is a pre-clinical, private biotech based in Chicago, IL, leveraging a drug repurposing platform for ophthalmology. The company's pipeline includes BTV100 for dry eye disease and BT300 for post-ocular surgery inflammation, both in pre-clinical development. With six U.S. patents pending and a team experienced in ocular drug development, BTV is positioned to advance novel treatments in large, underserved ophthalmic markets. The company is currently pre-revenue and focused on validating its candidates through the pre-clinical stage.

Ophthalmology

Technology Platform

Drug repurposing platform focused on unlocking new therapeutic potentials from known molecules through novel formulations or delivery mechanisms for ocular diseases.

Funding History

1
Total raised:$15M
Series A$15M

Opportunities

The large and growing markets for dry eye disease and post-surgical ocular care present significant commercial opportunities.
The drug repurposing strategy offers a potentially faster, lower-cost development pathway with reduced initial safety risk compared to novel drug discovery.

Risk Factors

High risk of pre-clinical failure for its lead candidates.
Heavy dependence on securing additional financing to advance programs.
Faces intense competition in the ophthalmology space from larger, well-resourced companies.

Competitive Landscape

The dry eye disease market is highly competitive with several established pharmaceuticals. The post-surgical inflammation market is dominated by generic steroids and NSAIDs. BioTheraVision's success hinges on demonstrating clear differentiation in efficacy, safety, or convenience compared to existing standards of care.

More companies in Small Molecule Drugs →More companies in United States →